微信小陈
微信小章| 产品名称： | IB4 |
|---|---|
| 商品货号： | TS211794 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications： | The antibody is specific for human CD18, and inhibits CD18 dependent activities. |
| Storage Conditions： | liquid nitrogen vapor phase |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | Spleen cells were fused with P3X63Ag8U.1 mouse myeloma cells. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against human CD18 (leukocyte antigen) |
| Cellular Products： | immunoglobulin; monoclonal antibody; against human CD18 (leukocyte antigen) |
| Comments： | Animals were immunized with human peripheral blood monocytes. Spleen cells were fused with P3X63Ag8U.1 mouse myeloma cells. The antibody is specific for human CD18, and inhibits CD18 dependent activities. |
| Complete Growth Medium： | Culture Medium: RPMI 1640 medium, 90%; fetal bovine serum, 10%. |
| Subculturing： | Protocol: Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10(5) cells/ml. Interval: Maintain between 1 X 10(5) and 1 X 10(6) cells/ml. Medium Renewal: Every 2 to 3 days |
| Cryopreservation： | Freeze medium: Complete growth medium supplemented with 7.5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions： | Temperature: 37.0°C |
| Isotype： | IgG2a kappa |
| Name of Depositor： | Rockefeller Univ. |
| U.S. Patent Number： | |
| References： | Van Voorhis WC, et al. Specific antimononuclear phagocyte monoclonal antibodies. Application to the purification of dendritic cells and the tissue localization of macrophages. J. Exp. Med. 158: 126-145, 1983. PubMed: 6190974 Wright SD, Tuomanen E. Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma. US Patent 5,147,637 dated Sep 15 1992 Wright SD, et al. Identification of the C3bi receptor of human monocytes and macrophages by using monoclonal antibodies. Proc. Natl. Acad. Sci. USA 80: 5699-5703, 1983. PubMed: 6225125 |